Firivumab
- CAS No.
- 1443004-15-6
- Chemical Name:
- Firivumab
- Synonyms
- Firivumab;Research Grade Firivumab;Research Grade Firivumab (DVV03802)
- CBNumber:
- CB48080916
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Firivumab 95.00% | CS-0628712 | 1mg | $325 |
| Firivumab 95.00% | CS-0628712 | 5mg | $812 |
| Firivumab 95.00% | CS-0628712 | 10mg | $1300 |
| Firivumab >98% | AA02AP0S | 1mg | $369 |
| Firivumab >98% | AA02AP0S | 5mg | $869 |
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | JC5C9983X2 |
Firivumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628712 | Firivumab 95.00% | 1443004-15-6 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0628712 | Firivumab 95.00% | 1443004-15-6 | 5mg | $812 | 2026-06-04 | Buy |
| ChemScene | CS-0628712 | Firivumab 95.00% | 1443004-15-6 | 10mg | $1300 | 2026-06-04 | Buy |
| aablocks | AA02AP0S | Firivumab >98% | 1443004-15-6 | 1mg | $369 | 2026-06-02 | Buy |
| aablocks | AA02AP0S | Firivumab >98% | 1443004-15-6 | 5mg | $869 | 2026-06-02 | Buy |
Firivumab Chemical Properties,Uses,Production
Uses
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3].
in vivo
Firivumab (CT-P22; CT120; 7.5-30 mg/kg; IP; Twenty-four hours post-infection) shows 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group[1].
CT-P27 (adding 7.5 mg/kg Firivumab and 7.5 mg/kg CT149) shows full protection in A/California/04/09 (H1N1)-treated mice[1].
| Animal Model: | Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)[1] |
| Dosage: | 7.5, 15, 30 mg/kg |
| Administration: | IP; Twenty-four hours post-infection |
| Result: | Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group. Could not protect mice from H3N2 infection. |
References
[1] Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172. DOI:10.1371/journal.pone.0236172
[2] John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463. DOI:10.1101/cshperspect.a038463
[3] Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1.
Firivumab Preparation Products And Raw materials
Raw materials
Preparation Products
Firivumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9865 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7085 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11972 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5432 | 58 |
| Wanxin Biotechnology (Jiaxing) Co., LTD | 0573-83568680 18057391398 | 3956524501@qq.com | China | 1442 | 58 |
| Atagenix Laboratories | 027-87008169 17762441161 | info@atagenix.com | China | 9998 | 58 |
| AntibodySystem Laboratories SAS | -- | support@antibodysystem.com | China | 6738 | 58 |
